Table 1 LNP drugs that have received regulatory approval from the FDA or EMA

From: The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

NameEncapsulated drugIndicationYear approvedCompany
AmBisomeAmphotericin BFungal infections Leishmaniasis1990 (Europe)
1997 (USA)
Gilead
Doxil/CaelyxDoxorubicinKaposi’s sarcoma
Ovarian cancer
Breast Cancer
1995 (USA)
1999 (USA)
2003 (Europe)
Johnson& Johnson
DaunoXomeDaunorubicinKaposi’s sarcoma1996 (Europe), 1996 (USA)Galen
MyocetDoxorubicinBreast cancer2000 (Europe)Cephalon
AbelcetAmphotericin BAspergillosis1995 (USA)Enzon
AmphotecAmphotericin BInvasive aspergillosis1996 (USA)Intermune
VisudyneVerteporfinWet macular degeneration2000 (USA)QLT
MarqiboVincristineAcute lymphoblastic leukemia2012 (USA)Spectrum Pharma
OnyvideIrinotecanMetastatic pancreatic cancer2015 (USA)Ipsen Biopharma
VyxeosDaunorubicin, CytarabineAcute lymphocytic leukemia2017 (USA)Jazz Pharma
OnpattrosiRNA targeting transthyretinTransthyretin induced amyloidosis (hATTR)2018 (USA), 2018 (Europe)Alnylam Pharmaceuticals